PARP1 and Huntington disease: Other disease models in which PARP1 inhibitors have cytoprotective effects include Alzheimer's disease (AD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) [22], experimental retinal detachment [23], as well as ischemia/reperfusion injury of the kidney or the liver [24, 25].